Idarubicin inserts itself into DNA and prevents DNA from unwinding by interfering with the enzyme topoisomerase II.
The recommended dose in dogs over 15 kg body weight is 22 mg/m2.
Adverse hematologic events (neutropenia and thrombocytopenia) are common and generally correlate with higher plasma concentrations of idarubicin and idarubicinol (metabolite).
- Vail DM et al (2012) Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma. J Vet Intern Med 26(3):608-613
- Strolin Benedetti M et al (1991) Stereoselectivity of idarubicin reduction in various animal species and humans. Xenobiotica 21(4):473-480